Navigation Links
Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure
Date:11/10/2008

ctive was proof-of-concept and dose and endpoint selection. In Phase III RELAX-AHF, the objective is to confirm safety and efficacy. Patients selected for the study presented to the hospital with dyspnea (breathlessness) due to AHF and with elevated blood pressure and renal dysfunction. The Pre-RELAX-AHF/RELAX-AHF study was designed and conducted in collaboration with Momentum Research, headed by Dr. Gad Cotter.

Marco Metra, M.D., Professor of Cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, was also a speaker at the symposium. "Patients with AHF remain a major clinical challenge with extremely high morbidity and mortality rates. Promising new agents such as relaxin are needed to treat these patients and improve their outcomes. The data from the Phase II study met the objectives of the proof-of-concept Pre-RELAX-AHF study, allowing the selection of the appropriate dose and endpoints for further study. Progression to the Phase III portion of the study is now clearly warranted," said Dr. Metra.

According to the AHA, heart failure is a costly syndrome contributing to more than three million hospitalizations each year in the U.S. The great majority of patients with acute heart failure have fluid accumulation in the lungs (congestion) that causes shortness of breath (dyspnea) and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men
'/>"/>

SOURCE Corthera Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
2. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
3. Misonix Announces Interim Distribution Agreement for Italy
4. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
5. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
8. LPBP Inc. - Re-filing certification of interim filings
9. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
10. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: SEED) ... supplier of crop seeds in China , ... fiscal year 2014 ended September 30, 2014, before the market ... will host a teleconference on January 8, 2015, at 8:00 ... time to discuss the results. To participate in the call, ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin ... today that they have joined forces to support Canadian entrepreneurs ... , Virgin Group Founder was at the MaRS Centre to ... new, national impact venture fund. This fund has $1 million ... Vancouver -based Mindset Social Innovation Foundation, founded ...
(Date:12/13/2014)... Taiwan (PRWEB) December 12, 2014 Trend ... indicators in overall global economic growth, Eugene Arthurs, CEO ... photonics , said in a featured talk at OPTIC ... December at the National Chung Hsing University in Taichung. ... being integrated into future energy supplies and soon to ...
(Date:12/13/2014)... York, New York (PRWEB) December 13, 2014 ... of its global network and Cold Chain capabilities, and ... Control Tower in Paris, France, to serve Life Science ... new facility equipped with a controlled-ambient warehouse, will provide ... storage for vaccines and investigational drugs, patient-clinical specimens, API, ...
Breaking Biology Technology:Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2
... California. , Dynal : 400+ employees worldwide, 87 in ... Norway. Brown Deer, Wis. California-based ... ASA , whose U.S. operations are based in Brown ... million. , ,Invitrogen has considered the acquisition since ...
... venture capital performance in the U.S. during 2004. , ,We ... share of this investment as well as how the life science ... detailed look at how the life science industry in the Midwest ... report. , ,Still, I was able to ferret out some ...
... written about the important impact that generic pharmaceutical drugs ... Their rise and growth spurs Big Pharma to invest ... Americans not having any kind of medical health insurance ... medicines from Canada being rapidly shut by U.S. pharmaceutical ...
Cached Biology Technology:Invitrogen to buy Norwegian biotech with operations in Brown Deer 2Midwest VC investment up in 2004, but number of deals down 2Midwest VC investment up in 2004, but number of deals down 3Pharmas will be forced into generic-drug strategy 2Pharmas will be forced into generic-drug strategy 3
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... 2013, New York, NY Ludwig researchers have elucidated a ... metabolize glucose to generate the energy and raw materials ... in Cell Metabolism , the Ludwig Cancer Research ... harnesses the mechanism to resist targeted therapies that should ...
... steer clear of dirt but their wild cousins can,t be ... a result. A study of wild mice has shown ... material and droppings left by other mice. Choosing a ... an increased risk of disease from other animals, dirt, the findings ...
... that individual "molecular muscles" within cells respond to different types ... the environment and appropriately adapt their shapes and activities. ... the journal Nature Materials , specifically sheds light on ... A computer model the researchers developed, they add, ...
Cached Biology News:Targeting cancer's sweet tooth 2Targeting cancer's sweet tooth 3Clean living is a luxury wild animals can't afford, study suggests 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3
... Protein Solubility Service, We deliversoluble protein ... SOS technology yields the best soluble protein ... on each clone submitted , Powerful results ... new protein Solubility Optimization Service (SOS) uses ...
... Multi-Disciplinary Team The ... is a stand-alone work center dedicated ... array manufacturing. The facilitys experienced project ... Planning and Marketing professionals, work closely ...
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... commonly used technique for studying protein function ... on SDS-PAGE and transferred to a membrane ... are probed with specific antibodies. Unlike nucleic ... Southern and Northern blots, it has been ...
Biology Products: